Acerus is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.
Founded in 2008, Acerus has quickly grown into a fully integrated company with expertise in all stages of the pharmaceutical product lifecycle, and focus in the therapeutic areas of Men’s Health (Urology) and Women’s Health (Hormone Replacement Therapy, Female Sexual Dysfunction).
Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO®, a product utilizing our licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG and approved in 39 countries worldwide, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and/or to restore a healthy vaginal environment. TEFINA™, a “use as required” testosterone nasal gel, is our drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.
Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP).